It was an experimental study, where a novel assay was designed for the targeted variant, and a cohort of hormone receptor positive breast cancer patients were genotyped for the CYP2D6*10 variant using the optimized and validated assay. The gene discussed is NR4A1; the disease is breast carcinoma.